Damora Therapeutics, Inc. (DMRA)
Damora Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Waltham, MA, US. The stock last traded at $18.44, down 1.60% on the session, giving a market capitalisation of $1.14B. On trailing twelve-month figures it carries a trailing P/E of -0.15, a net margin of 0.0%. Its beta of 1.44 implies it has historically moved more than the broad market.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Damora Therapeutics, Inc. is most often compared with the following Healthcare names: